<del id="1vnmyn"><th id="1vnmyn"><blockquote id="1vnmyn"></blockquote></th></del><label id="1vnmyn"><code id="1vnmyn"><address id="1vnmyn"></address></code><dfn id="1vnmyn"><button id="1vnmyn"></button><dfn id="1vnmyn"></dfn><ul id="1vnmyn"></ul><acronym id="1vnmyn"></acronym></dfn></label><button id="1vnmyn"><big id="1vnmyn"><abbr id="1vnmyn"></abbr></big><tt id="1vnmyn"><sup id="1vnmyn"></sup><ins id="1vnmyn"></ins></tt><thead id="1vnmyn"><address id="1vnmyn"></address><q id="1vnmyn"></q><style id="1vnmyn"></style></thead><form id="1vnmyn"><thead id="1vnmyn"></thead><dir id="1vnmyn"></dir><table id="1vnmyn"></table><sup id="1vnmyn"></sup><button id="1vnmyn"></button></form></button><span id="1vnmyn"><small id="1vnmyn"><address id="1vnmyn"></address></small><option id="1vnmyn"><dt id="1vnmyn"></dt></option><noscript id="1vnmyn"><bdo id="1vnmyn"></bdo></noscript><select id="1vnmyn"><dt id="1vnmyn"></dt><abbr id="1vnmyn"></abbr><small id="1vnmyn"></small><thead id="1vnmyn"></thead><pre id="1vnmyn"></pre></select></span><bdo id="1vnmyn"><dt id="1vnmyn"><fieldset id="1vnmyn"></fieldset></dt><tr id="1vnmyn"><fieldset id="1vnmyn"></fieldset></tr><kbd id="1vnmyn"><b id="1vnmyn"></b><noscript id="1vnmyn"></noscript><abbr id="1vnmyn"></abbr><button id="1vnmyn"></button><label id="1vnmyn"></label></kbd></bdo>
            • <tbody id="hyujn6"><span id="hyujn6"><sup id="hyujn6"></sup><dd id="hyujn6"></dd><kbd id="hyujn6"></kbd></span></tbody><tbody id="hyujn6"><tr id="hyujn6"><tbody id="hyujn6"></tbody><font id="hyujn6"></font></tr><select id="hyujn6"><dt id="hyujn6"></dt></select><tr id="hyujn6"><label id="hyujn6"></label><dd id="hyujn6"></dd><q id="hyujn6"></q></tr><noscript id="hyujn6"><style id="hyujn6"></style><table id="hyujn6"></table><big id="hyujn6"></big></noscript></tbody><optgroup id="hyujn6"><i id="hyujn6"><legend id="hyujn6"></legend><option id="hyujn6"></option></i><label id="hyujn6"><big id="hyujn6"></big></label><q id="hyujn6"><kbd id="hyujn6"></kbd><sup id="hyujn6"></sup><legend id="hyujn6"></legend><thead id="hyujn6"></thead></q><sup id="hyujn6"><ol id="hyujn6"></ol><ins id="hyujn6"></ins><acronym id="hyujn6"></acronym><b id="hyujn6"></b></sup><option id="hyujn6"><form id="hyujn6"></form><th id="hyujn6"></th><button id="hyujn6"></button><strong id="hyujn6"></strong><optgroup id="hyujn6"></optgroup></option></optgroup><dt id="hyujn6"><big id="hyujn6"><noframes id="hyujn6">
                        1. <bdo id="80evbk"></bdo><dir id="80evbk"></dir>

                          南京恒道醫藥科技有限公司受珠海億勝委托開發的單劑量幹眼症治療藥物****滴眼液近日取得CNDA頒發的藥品注冊生産批件。

                          我司2013年受珠海億勝委托開發完成該項目的藥學研究及生産注冊的全部工作。因國家審評政策等原因,該項目曆經5年終獲生産批件。本品在現今極其嚴格的注冊環境下順利通過審評並取得藥品生産批件,表明我司研發團隊在藥學研究和藥品注冊等各個環節均有著雄厚的實力和豐富的實戰經驗。

                          感謝珠海億勝對我司的信任和委托以及整個項目研發及注冊過程中的配合。我司將一如既往的爲重庆159彩票首页藥企提供“專業、專心、客戶至上”的服務。



                          2018年08月18日

                          我司爲珠海億勝服務的****滴眼液取得國家藥品監督管理局頒發的生産批件

                          添加時間:

                          X-POWER-BY FNC V1.0.0 FROM 自制52